Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Valsartan is an angiotensin II receptor antagonist (ARA) with actions similar to those of losartan. It is indicated in the treatment of hypertension, left ventricular dysfunction after myocardial infarction and in heart failure. Oral administration once or twice daily.
Its pharmacokinetic data (high percentage of protein binding, large volume of distribution and moderately high molecular weight) explain the null passage into breast milk observed, below the limit of detection. (Falconi 2024)
In addition, its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.
Dos lactantes cuyas madres tomaban sacubitril/valsartan no presentaron ningún problema. (Hale)